Bifogade filer
Kurs & Likviditet
Kalender
2024-10-24 | Kvartalsrapport 2024-Q3 |
2024-07-16 | Kvartalsrapport 2024-Q2 |
2024-05-15 | Ordinarie utdelning SOBI 0.00 SEK |
2024-05-14 | Årsstämma 2024 |
2024-04-25 | Kvartalsrapport 2024-Q1 |
2024-02-08 | Bokslutskommuniké 2023 |
2023-10-30 | Kvartalsrapport 2023-Q3 |
2023-08-15 | Extra Bolagsstämma 2023 |
2023-07-18 | Kvartalsrapport 2023-Q2 |
2023-05-10 | Ordinarie utdelning SOBI 0.00 SEK |
2023-05-09 | Årsstämma 2023 |
2023-04-27 | Kvartalsrapport 2023-Q1 |
2023-02-08 | Bokslutskommuniké 2022 |
2022-10-27 | Kvartalsrapport 2022-Q3 |
2022-07-19 | Kvartalsrapport 2022-Q2 |
2022-05-11 | Ordinarie utdelning SOBI 0.00 SEK |
2022-05-10 | Årsstämma 2022 |
2022-04-28 | Kvartalsrapport 2022-Q1 |
2022-02-10 | Bokslutskommuniké 2021 |
2021-10-28 | Kvartalsrapport 2021-Q3 |
2021-07-21 | Kvartalsrapport 2021-Q2 |
2021-05-05 | Ordinarie utdelning SOBI 0.00 SEK |
2021-05-04 | Årsstämma 2021 |
2021-05-04 | Kvartalsrapport 2021-Q1 |
2021-02-18 | Bokslutskommuniké 2020 |
2020-10-22 | Kvartalsrapport 2020-Q3 |
2020-07-16 | Kvartalsrapport 2020-Q2 |
2020-05-14 | Ordinarie utdelning SOBI 0.00 SEK |
2020-05-13 | Årsstämma 2020 |
2020-04-29 | Kvartalsrapport 2020-Q1 |
2020-02-13 | Bokslutskommuniké 2019 |
2019-10-31 | Kvartalsrapport 2019-Q3 |
2019-07-17 | Kvartalsrapport 2019-Q2 |
2019-05-10 | Ordinarie utdelning SOBI 0.00 SEK |
2019-05-09 | Årsstämma 2019 |
2019-04-25 | Kvartalsrapport 2019-Q1 |
2019-02-20 | Bokslutskommuniké 2018 |
2018-10-31 | Kvartalsrapport 2018-Q3 |
2018-07-18 | Kvartalsrapport 2018-Q2 |
2018-05-11 | Ordinarie utdelning SOBI 0.00 SEK |
2018-05-09 | Årsstämma 2018 |
2018-04-26 | Kvartalsrapport 2018-Q1 |
2018-02-22 | Bokslutskommuniké 2017 |
2017-10-25 | Kvartalsrapport 2017-Q3 |
2017-07-19 | Kvartalsrapport 2017-Q2 |
2017-05-05 | Ordinarie utdelning SOBI 0.00 SEK |
2017-05-04 | Årsstämma 2017 |
2017-04-28 | Kvartalsrapport 2017-Q1 |
2017-02-16 | Bokslutskommuniké 2016 |
2016-10-27 | Kvartalsrapport 2016-Q3 |
2016-07-15 | Kvartalsrapport 2016-Q2 |
2016-05-24 | Årsstämma 2016 |
2016-05-20 | Ordinarie utdelning SOBI 0.00 SEK |
2016-04-27 | Kvartalsrapport 2016-Q1 |
2016-02-26 | Bokslutskommuniké 2015 |
2015-10-29 | Kvartalsrapport 2015-Q3 |
2015-07-17 | Kvartalsrapport 2015-Q2 |
2015-05-07 | Ordinarie utdelning SOBI 0.00 SEK |
2015-05-06 | Årsstämma 2015 |
2015-05-06 | Kvartalsrapport 2015-Q1 |
2015-02-19 | Bokslutskommuniké 2014 |
2014-10-30 | Kvartalsrapport 2014-Q3 |
2014-10-30 | Analytiker möte 2014 |
2014-07-18 | Kvartalsrapport 2014-Q2 |
2014-05-09 | Ordinarie utdelning SOBI 0.00 SEK |
2014-05-08 | Kvartalsrapport 2014-Q1 |
2014-05-08 | Årsstämma 2014 |
2014-02-20 | Bokslutskommuniké 2013 |
2013-11-05 | Kapitalmarknadsdag 2013 |
2013-11-05 | Analytiker möte 2013 |
2013-10-30 | Kvartalsrapport 2013-Q3 |
2013-07-18 | Kvartalsrapport 2013-Q2 |
2013-04-29 | Ordinarie utdelning SOBI 0.00 SEK |
2013-04-26 | Årsstämma 2013 |
2013-04-26 | Kvartalsrapport 2013-Q1 |
2013-02-21 | Bokslutskommuniké 2012 |
2012-10-30 | Kvartalsrapport 2012-Q3 |
2012-10-30 | Analytiker möte 2012 |
2012-07-19 | Kvartalsrapport 2012-Q2 |
2012-04-27 | Ordinarie utdelning SOBI 0.00 SEK |
2012-04-26 | Kvartalsrapport 2012-Q1 |
2012-04-26 | Årsstämma 2012 |
2012-02-23 | Bokslutskommuniké 2011 |
2011-11-29 | Kapitalmarknadsdag 2011 |
2011-10-20 | Kvartalsrapport 2011-Q3 |
2011-08-24 | Extra Bolagsstämma 2011 |
2011-07-19 | Kvartalsrapport 2011-Q2 |
2011-04-29 | Ordinarie utdelning SOBI 0.00 SEK |
2011-04-28 | Årsstämma 2011 |
2011-04-20 | Kvartalsrapport 2011-Q1 |
2011-02-23 | Bokslutskommuniké 2010 |
2010-10-26 | Kvartalsrapport 2010-Q3 |
2010-07-20 | Kvartalsrapport 2010-Q2 |
2010-04-28 | Ordinarie utdelning SOBI 0.00 SEK |
2010-04-27 | Kvartalsrapport 2010-Q1 |
2009-04-29 | Ordinarie utdelning SOBI 0.00 SEK |
2008-04-25 | Ordinarie utdelning SOBI 0.00 SEK |
2007-05-04 | Ordinarie utdelning SOBI 0.00 SEK |
Beskrivning
Land | Sverige |
---|---|
Lista | Large Cap Stockholm |
Sektor | Hälsovård |
Industri | Läkemedel & Handel |
The Board of Directors remains fully committed to Sobi and Sobi's strategy
Håkan Björklund, Chairman of the Board of Directors: "We are as committed as ever to helping people with rare diseases. The Board and I have confidence in Sobi's vision: To be recognised as a global leader in rare diseases. We have taken important steps towards this vision in recent years, and we are proud of the clear progress made.
We have a strong belief in Sobi's strategy and the opportunities ahead. Sobi's strategy is clear, and we are confident that the company will continue to focus and deliver on the objectives: Invest in Haematology, grow in Immunology and Specialty Care, expand globally, and invest in the pipeline. Sobi has several important launches of new medicines as well as R&D projects to advance, while continuing to expand the geographical presence."
Commenting on the bid process, the Chairman said "As we have announced, the Board supported the public offer by Advent and GIC, as we believed in the strategic merit of the transaction. Subsequent discussions regarding the potential execution of the transaction have been directly dealt with between the bidding consortium and Sobi shareholders."
Ending the statement, the Chairman said: "Sobi has a clear mission: To develop and deliver innovative therapies and services to improve the lives of people living with rare diseases. This remains unchanged."
Contacts
To contact the Sobi Investor Relations Team, please click here (https://www.sobi.com/en/ir-contacts). For Sobi Media contacts, click here (https://www.sobi.com/en/media).
Sobi™
Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Sobi is providing sustainable access to innovative therapies in the areas of haematology, immunology, and specialty indications. Today, Sobi employs approximately 1,500 people across Europe, North America, Middle East, and Asia. In 2020, Sobi's revenues amounted to SEK 15.3 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. You can find more information about Sobi at sobi.com. (https://www.sobi.com)